Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03197922 · ClinicalTrials.gov registry record · Phase 3
Treatment of Encopresis in Children With Autism Spectrum Disorders
A Phase 3 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 3
- Development phase
- 117
- Enrollment target
NCT03197922 is a Phase 3 study that has completed, run by Emory University. The registered enrollment target is 117 participants.
The verdict
NCT03197922, a Phase 3 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 117 participants
- Enrollment target
Study Summary
This study is comparing a multidisciplinary intervention for encopresis (MIE), consisting of both medical and behavioral components to treatment as usual control (TAU). Participants are first screened by a pediatric gastroenterologist and assessed and treated for any constipation or other potential medical complications. Following this, caregivers collect data on bowel movements and continence during a home baseline lasting no less than 14 days and no more than 21 days. Participants randomly assigned to treatment as usual or the treatment group, and begin attending daily appointments in clinic for 2 weeks. At appointments, the behavior team implements structured sits on the toilet to promote independent bowel movements (BMs). If an independent BM does not occur, the study team will administer a suppository to promote rapid release of the bowels and prompt the child to remain on the toilet following administration. In doing so, continent bowel movements are predictably evoked while the child is on the toilet, allowing for reinforcement with praise and preferred toys/activities. Eventually, suppositories are gradually decreased until the child is having BMs independently. Caregivers are trained to continue implementing the intervention following the clinic-based portion. The purpose of the current study is to evaluate MIE using a large randomized clinical trial (RCT), addressing the Department of Defense Autism Research Program, Area of Interest of Therapies to Alleviate Conditions Co-Occurring with autism spectrum disorder (ASD). The researchers will recruit 112 children diagnosed with ASD, randomizing them to two weeks of MIE, or treatment as usual (TAU) consisting of behavioral consultation and medical intervention. This study will evaluate MIE compared to TAU and determine the optimal treatment length.
Interventions
- DRUG Glycerin Suppository
- BEHAVIORAL MIE Treatment
- COMBINATION_PRODUCT Treatment as Usual (TAU)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2022-11-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03197922
The ClinicalTrials.gov registry entry for NCT03197922 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Glycerin Suppository is the first listed.
NCT03197922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03197922 about?
NCT03197922 is a clinical study titled "Treatment of Encopresis in Children With Autism Spectrum Disorders". This study is comparing a multidisciplinary intervention for encopresis (MIE), consisting of both medical and behavioral components to treatment as usual control (TAU). Participants are first screened by a pediatric gastroenterologist and assessed and treated for any constipation or other potential ...
What is the current status of trial NCT03197922?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2017-10-25. Estimated completion is 2022-11-17.
What interventions are being tested in trial NCT03197922?
The interventions under investigation include: Glycerin Suppository (DRUG), MIE Treatment (BEHAVIORAL), Treatment as Usual (TAU) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03197922?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.